**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 6773**

**Columns:** **TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (8): Gastric cancer

**Subtotal gastrectomy for gastric cancer**

Santoro R *et al.* Subtotal gastrectomy for gastric cancer.

Roberto Santoro, Giuseppe Maria Ettorre, Eugenio Santoro

**Roberto Santoro, Giuseppe M Ettorre, Eugenio Santoro,** Department of General Surgery and Transplantation, San Camillo-Forlanini General Hospital, 00152 Rome, Italy

**Author contributions:** The idea was proposed by Santoro R; Santoro R and Ettorre GM drafted the initial manuscript; Santoro E reviewed and edited the draft; all authors approved the final manuscript before submission.

**Correspondence to: Roberto Santoro, MD, PhD,** Department of General Surgery and Transplantation, San Camillo-Forlanini General Hospital, Circ Gianicolense 87, 00152 Rome, Italy. santoro\_roberto@fastwebnet.it

**Telephone:** +39-6-58705408 **Fax:** +39-6-58704719

**Received:** October 28, 2013 **Revised:** June 10, 2014

**Accepted:** June 26, 2014

**Published online:**

**Abstract**

Although a steady decline in the incidence and mortality rates of gastric carcinoma has been observed in the last century worldwide, the absolute number of new cases/year is increasing because of the aging of the population. So far, surgical resection with curative intent has been the only treatment providing hope for cure; therefore, gastric cancer surgery has become a specialized field in digestive surgery. Gastrectomy with lymph node dissection for cancer patients remains a challenging procedure, which requires skilled, well-trained surgeons, who are very familiar with the fast-evolving oncologic principles of gastric cancer surgery. As a matter of fact, the extent of gastric resection and lymph node dissection depend on the size of the disease, and gastric cancer surgery has become a patient and “disease-tailored” surgery, ranging from endoscopic resection to laparoscopic assisted gastrectomy, and conventional extended multivisceral resections. Lymph node metastases represent the most important prognostic factor in patients that undergo curative resection. Lymph node dissection remains the most challenging part of the operation, due to the location of lymph node stations around major retroperitoneal vessels and adjacent organs, which are not routinely included in the resected specimen and need to be preserved in order to avoid dangerous intra- and post-operative complications. Hence, the surgeon is the most important non-TMN prognostic factor in gastric cancer. Subtotal gastrectomy is the treatment of choice for middle and distal-third gastric cancer, as it provides similar survival rates and better functional outcome compared to total gastrectomy, especially in early-stage disease with favorable prognosis. Nonetheless, the resection range for middle-third gastric cancer cases and the extent of lymph node dissection at early stages remains controversial. Due to the necessity of more extended procedure at advanced stages and the trend for more conservative treatments in early gastric cancer, the indication for conventional subtotal gastrectomy depends on multiple variables. This review aims at clarifying and defining the actual landmarks of this procedure, and the role it plays compared to the whole range of new and old treatment methods.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Gastric cancer; Gastrectomy; Lymphadenectomy; Laparoscopy; Endoscopy; Quality of life; Gastric stump cancer

**Core tip:** Gastric cancer surgical resection with curative intent is the only treatment providing hope for cure. Gastrectomy with lymph node dissection remains a challenging procedure, which should abide by well-defined oncologic principles. Subtotal gastrectomy is the treatment of choice for middle and distal-third gastric cancer; however, due to the necessity of more extended procedure at advanced stages and the trend for more conservative treatments in early gastric cancer, the indication for conventional subtotal gastrectomy depends on multiple variables. This review aims at defining the actual landmarks of this procedure, and the role it plays compared to the whole range of new and old treatment methods.

Santoro R, Ettorre GM, Santoro E. Subtotal gastrectomy for gastric cancer.*World J Gastroenterol* 2014; In press

**INTRODUCTION**

Although a steady decline in the incidence and mortality rates of gastric carcinoma has been observed in the last century worldwide, the absolute number of new cases/year is increasing due to the aging of the population[1]. In 1990, gastric cancer was the second commonest type of cancer in the world, with 800000 new cases and 650000 deaths per year. In 1997, the number of new cases raised to more than 1 million[2,3]. Incidence is higher in East Asia and Eastern Europe, with a smaller number of cases being recorded in North America and Northern Europe[4]. The aforesaid decline mainly concerns the Lauren intestinal (or well differentiated) type, which is more frequently reported in those regions where gastric cancer is endemic; it typically arises in the middle and distal third of the stomach, on a background of metaplasia affecting older male patients. On the other hand, the Lauren diffuse (or poorly differentiated) type is more common in low-risk areas. It has a steady incidence and tends to affect younger individuals, mainly females. Moreover, it often shows hereditary characteristics[5,6]. Gastric cancer is still a poor prognosis and high mortality disease, second only to lung cancer, especially in countries with lower incidence[7]. After Billroth’s first successful pylorectomy in 1881, and Schlatter’s first total gastrectomy in 1897 for gastric cancer, surgical resection is still the only treatment presently giving hope for cure[8,9]. In 1929, MacGuire noted that all the possibilities of partial resection of the stomach and anastomosis with the duodenum and jejunum had been developed[10]. He reported excellent results in terms of postoperative morbidity and mortality rates, after subtotal gastrectomy in 16 patients. However, a carcinoma of the pylorus with obstruction was described in one patient only, with the others suffering from gastric and duodenal peptic ulcer. McGuire’s report shows that surgeons have been familiar with partial gastrectomy for peptic disease for a very long time; however, the surgical approach to gastric cancer was standardized in Japan in the 1960s[11]. The first edition of the General Rules for Gastric Cancer Study was published by the Japanese Research Society for Gastric Cancer (JRSGC) in 1963, and the first English edition was based on the 12th Japanese edition and was published in 1995[12]. In Japan, the incidence is 20-folds the incidence in United States and, while the incidence of proximal tumors is increasing in the West, distal tumors continue to predominate in the Land of the rising sun. Such important epidemiologic differences entail different diagnostic and therapeutic strategies and prognosis. In Japan, a mass screening program has been in place since the ‘60s, and early detection of the disease, combined with improved operative techniques, has led to a significant decrease in mortality[13]. In a large evaluation of 10000 patients treated between 1962 and 1989 at Kyushu University of Fukuokoa, Japan, most carcinomas were found in the two distal thirds of the stomach, and a large part of patients underwent subtotal distal gastrectomy[14]. Total gastrectomy was performed for widespread disease, proximal location, multifocal disease, or f due to extensive dissection of the lymph nodes. According to the Registry of the Japanese Research Society for Gastric Cancer the incidence of stage-I gastric cancer in 1991 was 55.5%, while subtotal gastrectomy accounted for 69.3%[15]of all surgeries. The same Registry showed a cumulative 5-years survival rate of 68.2%. In a multi-institutional randomized controlled trial carried out on behalf of the Japan Clinical Oncology Group, comparing D2 and extended para-aortic lymphadenectomy in advanced gastric cancer, the incidence of subtotal gastrectromy was 61.1%[16]. In Western countries, gastric cancer prognosis has been improving over the last 40 years; however, it remains quite poor[17]. In Europe, 5-year survival varies depending on the Country, ranging from less than 10% to nearly 25%[18]. In the past, gastric cancer located in the distal third of the stomach was treated by total or subtotal gastrectomy, depending on the surgeon’s experience. The “en principe” total gastrectomy was proposed in the ‘70s to secure better loco-regional tumor control compared to subtotal gastrectomy[19,20]. However, said procedure did not gain worldwide acceptance, and several surveys carried out at that time showed that the incidence of subtotal gastrectomy varied between 20% and 70%[21-26]. Moreover, several non-randomized series published in the ‘80s did not show any survival-related benefit of total gastrectomy compared to subtotal gastrectomy[27-31]. Lastly, two randomized trials published in 1989 and 1999 respectively, comparing the survival rates for total and subtotal gastrectomy for gastric cancer located in the distal third, reported similar survival rates for the two procedures[32,33]. Since then, subtotal gastrectomy has been considered as the treatment of choice in distal and middle-third gastric cancer, provided that the resection margins fall in healthy tissue, and this also in Western Countries. The extent of a gastric resection is not technically challenging for general surgeons, and the extent of the lymph node (LN) dissection required in the treatment of gastric cancer with curative intent is the most challenging part of any operation. In the ‘80s and 90s, the role of lymph node dissection was also assessed worldwide. The topographic pattern of lymph node metastases was largely described and the range of the D1, D2, D3 and D4 LN dissections was validated in Japan[34,35]. A standardized LN dissection was developed and it was routinely used nationwide with therapeutic benefits and good long-term survival. In Western countries, extended lymph node dissection was not popular due to higher morbidity and mortality rates and no survival benefits[36-39]. Finally, the long-term results of two European studies showed significant improvement in survival rates due to D2 lymph node dissection in patients with stage-II disease; moreover, the study clearly identified the patients who may benefit from D2 LN dissection, also in Western countries[40,41]. , In those years, the benefits of more extended D3 and D4 LN dissections had not been clearly demonstrated compared to D2 lymphadenectomy, and they also showed higher incidence of complications42-43]. Based on the aforementioned results, the Japanese Gastric Cancer Association updated the classification of gastric cancer and the guidelines for surgical treatment according to clinical stage in 1998 and in 2011 respectively[44,45]. This review aim at pointing out the role of subtotal gastrectomy in the treatment of gastric cancer; it will focus on the extent of gastric resection, the extent of lymphadenectomy, the type of reconstruction in the era of minimal invasive approach and endoscopic resection.

**ONCOLOGIC PRINCIPLES OF SUBTOTAL GASTRECTOMY: THE RATIONALE**

***Subtotal gastrectomy vs. total gastrectomy***

Curative resection is the only chance for cure in patients with resectable gastric cancer. It aims at ensuring complete removal of the tumor, by providing adequate longitudinal and circumferential resection margins. Subtotal gastrectomy is the gold standard treatment for early-stage gastric cancer located in the distal third of the stomach. The results of two randomized studies carried out in European countries have shown that subtotal gastrectomy for distal-third gastric cancer entails similar long-term survival results as total gastrectomy, with lower morbidity and mortality rates and better postoperative quality of life[32,33]. There are several advantages in performing more conservative surgery. Subtotal gastrectomy entailed lower short-term morbidity and mortality rates and shorter hospital stay, as well as higher calorie intake and better nutritional status with improved quality of life in the long run. A very large multicentric prospective study on more than 4,000 patients carried out in Italy in the ‘80s did not find any significant difference in terms of long-term survival between the two procedures[46]. However, many years later, surgeons have not reached consensus yet; as a matter of fact, the supporters of the “en principe” total gastrectomy advocate maintain that it allows better local tumor control of the disease. The extent of gastric resection is not a prognostic factor, whereas the adequate LN clearance of the LN stations beyond the perigastric ones is the most important surgical prognostic factor in both early and advanced gastric cancer[35,47-50]. In patients with distal-third gastric cancer, total gastrectomy without an adequate lymphadenectomy would be an oncological surgical mistake, as it is at the same time an overtreatment from the gastric resection standpoint, and an undertreatment from the LN dissection standpoint. There is no advantage in extending the resection to the whole stomach; however, the extent of gastric resection depends on the site and size of the primary tumor. According to a prospective randomized study carried out in the ‘80s in Italy, the resection line should provide a safe 3-6 cm resection margin in case of Lauren intestinal or diffuse gastric cancer, respectively[33]. However, according to the Japanese Gastric Cancer Association guidelines,a proximal margin of at least 3 cm is recommended for T2 or deeper tumors with an expansive growth pattern (Types 1 and 2), and 5 cm is recommended for those with infiltrative growth pattern (Types 3 and 4) [45]. Total gastrectomy may be required in those cases with poorly differentiated histologic type located in the angularis portion of the stomach, who are likely to show a submucosal invasion along the lesser curvature towards the cardia with a high risk of microscopic invasion of the transection line[51], or in patients with multicentric disease. Total gastrectomy may also be required in patients suffering from distally located gastric cancer with multiple lymph node metastases and advanced stages, in order to allow an extended D2 or D3 lymph node dissection. In such cases, an aggressive surgical approach, including multivisceral resections, represents the only hope for cure. Total gastrectomy has been advocated as a prophylactic treatment in the event of E-cadherin gene mutation in association with familial gastric cancer, too[52,53].

***General lymph node dissection rules***

Lymphatic spread is the most relevant prognostic factor in patients with gastric cancer resected for cure. Lymph node status and ratio are the most important prognostic factors[35,47-49,54,55]. The importance of adequate lymphadenectomy as part of a potentially curative resection has been recognized in Western countries as well[39,41,56-58]. For absolutely curative resection, lymphatic dissection must be a level higher than the highest echelon of metastatic lymph nodes, in addition to tumor free margin. Appropriate LN dissection is also important for accurate staging. The number of retrieved LNs has been validated as a method of evaluating the adequacy of LN dissection, but data collection from each LN station needs considerable effort from both surgeons and pathologists. The number of LN metastases has been validated as a better prognostic indicator compared to the location of the LN metastases[48,49], and the staging system was updated in the 2010 UICC/TNM 7the edition[59]. According to the new system, pN1 is defined as LN metastases in 1 to 2 LNs, pN2 is defined as LN metastases in 3 to 6 LNs, N3a in patients with 7 to 15 metastatic LN and N3b in patients with more than 16 LNs metastases. At the same time, the classifications of the LN stations and LN dissections were also updated.

*Lymph node stations classification.* In the past, 16 different LN stations had been identified surrounding the stomach[12]. The perigastric nodes were defined as N1 nodes (station 1 to 6). N2 nodes corresponded to the nodes around the main vessels originating from the celiac trunk (station 9), being the left gastric, common hepatic, splenic artery and splenic hilum and arteries (stations 7, 8, 11 and 10, respectively). Nodes at the hepatoduodenal ligament (station 12), at the retropancreatic region (station 13), and at the root of the mesentery (station 14) were defined as N3, whereas those along the middle colic vein (station 15) and para-aortic nodes (station 16) were classified as N4. This topographic classification remains very popular among surgeons and still represents a milestone knowledge that helps surgeons to perform lymph node dissection correctly. However, nowadays, it has poor clinical significance. As a matter of fact, according to the Japanese classification of gastric carcinoma, lymph node stations 1–12 and 14v are nowadays defined as “regional” gastric lymph nodes, whereas metastasis to any other nodes is classified as “M1”.

***Definition of lymph node dissections***

Lymph node (LN) dissection was initially classified as D1 to D4, depending on the extent and removal of each LN station according to the primary tumor location. In distal subtotal gastrectomy, D1 included removal of only LN stations 1, 3, 4, 5, 6, and 7 surrounding the stomach, whereas D2 included D1 LN dissection and station 8a, 12a, 9, and 11. D3 and D4 LN dissections occur when the other LN stations are removed. This system has been revised and, nowadays, it reflects the number of retrieved lymph nodes rather than their location. Hence it is as follows: D0 when less than 15 nodes are reported, D1 when 15 to 25 nodes are removed, and D2 when more than 25 nodes are reported in the pathological findings[12,40,49,60]. As a matter of fact, the number of LNs itself cannot give any information about the extent of LN dissection. The original N1–3 and D1–3 definitions are far more complicated: lymph node groups are defined as Compartments 1-3, and depend on the location of the primary tumor according to which each lymph node station is given a group number (1, 2, 3, or M)[44].

***Oncologic principles of lymph node dissection in distal subtotal gastrectomy***

The rate and number of metastatic LNs increases with the depth of tumor invasion through the gastric wall layers, and it shows a clear relationship with survival[35,61-63]. This rate is low in early gastric cancer (EGC), and the Japanese Gastric Cancer Association recommended a D2 LN dissection in most gastric cancer. However, less extensive LN dissection was approved in patients with T1 cancer and clinical node-negative disease. The incidence of LN metastases in lower-third gastric cancer at each LN station according to the depth of tumor invasion was well described in a recent detailed report from the Seoul National University Hospital[62]. In said large series, curative resection for gastric cancer located in the distal third of the stomach was carried out with subtotal gastrectomy in 95.2% of the patients, 38.1% of whom suffered from advanced gastric cancer. The mean number of LNs was 37.6, and LN dissection was D2 or more extended in 57.1% of the surgeries. However, extended LN dissection was not performed in EGC, which accounted for 61 % of the cases. In the aforementioned study, a D1+ (D1 + station 7 and 8a) or D1+β (D1 + stations 7, 8a, and 9) LN dissection was performed in 43% of the patients. The incidence of LN metastases in mucosal EGC (pT1a) was very low, namely 1.1%, and a D1+ β LN dissection was suggested to be adequate. Instead, the incidence of LN metastases in submucosal EGC (pT1b) was as high as 23%. In particular, metastases to the second level LN stations (stations 7-11) and third level (LN stations 12-16) were detected in 5% of the patients. The authors concluded that, in patients with distal third submucosal cancer, D1+ β LN dissection entailed a risk of leaving metastatic nodes in 3% of cases, therefore D2 LN dissection was recommended. In other studies, the incidence of micro-metastases in N0 pT1 and pT2 was shown to be as high as 17%-23%, and such micro-metastases were correlated with the prognosis[64,65]. In case of EGC, the intraoperative histopatological evaluation of clinically suspected metastatic nodes or the sentinel node technique might be deemed suitable in a tailored LN dissection (D1 + β) strategy, and might avoid extended D2 LN dissection in selected N0 or N1 patients, who would not tolerate complications[66,67]. In this perspective, the minivasive approach has become the gold standard procedure for the treatment of EGC in Japan. In Western countries, the incidence of gastric cancer is low, no screening program has been approved, and most gastric cancer patients are diagnosed with advanced stage gastric cancer. For advanced gastric cancer (pT2-4) extended LN dissection is mandatory, because the rate of second level (LN stations 7-11) nodes metastases ranges between 10 and 20%. Several reports showed that extended LN dissection can be performed with low morbidity and mortality rates[16,68,69]. Pancreatosplenectomy, that was thought to be necessary in the past, remains a source of postoperative complications and it is not essential to adequate clearance of nodal stations along the splenic vessels in D2 LN dissection. Accurate dissection along the splenic vessels and the hepatic pedicle is the most challenging part of any gastric surgery for cancer, because it requires hepatobiliary and pancreatic surgery technical skills and training. General surgeons that have not gone through such training are more likely to perform inadequate gastric cancer surgery, especially in the event of advanced gastric cancer, when an aggressive surgical procedure is the only chance for cure[70]. The higher survival rates after D2 LN dissection compared to D1 surgery as reported by Japanese series have not been confirmed by European randomized trials[36,37. Some skeptics believe that extending LN dissection beyond perigastric stations entails more diagnostic than therapeutic benefit. However, patients with second-level node invasion who undergo D1 gastrectomy are likely to show early local recurrence because of inadequate LN dissection. Furthermore, such patients are understaged at the time of primary surgical treatment, which makes comparison with studies that use a more accurate staging inaccurate[71]. However, in other major nonrandomized studies, D2 lymphadenectomy was an independent prognostic factor and improved long term survival in patients with stage-II tumors[39,56]. Lastly, the very comprehensive results of the Dutch trial comparing D1 versus D2 lymphadenectomy showed that extended LN dissection is associated with lower loco-regional and gastric cancer-related death rates than D1 surgery[40]. Said study confirmed that significant long-term survival benefits were observed in stage-II patients (pT2N1 or pT3N0), as it had previously been shown by the German Gastric Study Group. The Dutch trial showed higher survival rates in D2 group N2 patients than D1 group patients and as N2 disease is difficult to identify preoperatively, the authors concluded that extended LN dissection might be beneficial when morbidity and mortality rates are very low. As a results, inadequate LN dissection accounts for more than half of the surgical failures, due to loco-regional recurrence, especially in those patients with second-level node metastases. A well designed Italian nonrandomized prospective multicentric study on patients with advanced gastric cancer invading the serosa (pT3) located in the gastric antrum, showed that subtotal gastrectomy with D2 LN dissection without splenectomy can be performed with low morbidity and mortality rates, and survival was even better than that of patient treated with total gastrectomy[72]. In the above-mentioned study, the choice of the surgical procedure (total or subtotal gastrectomy) was based on the surgeon’s preference. Subtotal gastrectomy was preferentially performed in older patients and when the surgeon believed the disease to be less aggressive, as demonstrated by the higher number of metastatic LN in the TG group. However, the type of surgery had no influence on the number of dissected nodes. The study also confirmed that extended LN dissection can be performed in patients with advanced gastric cancer located in the distal third of the stomach, suitable for subtotal gastrectomy. Total gastrectomy may become necessary when the lymphatic spread is beyond N2 LN stations. In the series reported by the Seoul national University Hospital, the incidence of total gastrectomy in 400 patients with advanced lower-third gastric cancer was 6%[62]. In clinical practice, D2 standard LN dissection becomes mandatory in the majority of the patients and less extensive lymphadenectomy can be performed in 10 to 20 % of the cases. Hence, surgeons need to have technical skills and clinical experience in order to treat most of gastric cancer patients, when surgery is the main treatment option. Results of trials on gastric cancer multidisciplinary management suggested that D2 surgery alone results in much better survival rates than less extensive surgery plus adjuvant chemotherapy and radiotherapy, as shown by the INT0116 trial. The Intergroup randomized trial confirmed that local recurrence of cancer is reduced by 50% after D2 resection[73,74].

With this tailored surgical approach, the Maruyama Index (MI) of unresected disease (as the quantitative measure of sum of the probabilities of metastases to regional LN station 1-12 that were not removed and left behind after primary surgical treatment) may remain low (< 5) within the limits of curative R0 resection, decreasing the risk of loco-regional recurrence and improving survival[75-78]. The Dutch D1 versus D2 trial was reanalyzed using the MI as a prognostic tool and the MI < 5 proved to be a strong predictor of survival by both univariate and multivariate analysis. D2 LN dissection should entail low MI in most patients, particularly in stage II and III gastric cancers[79]. Surgical experience and training are essential to perform high -quality gastric cancer surgery, and advanced gastric cancer patients are more likely to have a low MI curative surgery in high volume institutions rather than in low-volume hospitals. Subtotal gastrectomy is the first option in the treatment of middle and lower-third gastric cancer, regardless of the extent of LN dissection required to achieve curative R0 resection with low MI.

**ONCOLOGIC PRINCIPLES OF SUBTOTAL GASTRECTOMY: HOW TO PERFORM IT**

***Extent of gastric resection and the resection margin***

Nowadays, this procedure accounts for 23%-70% of all cancer gastrectomies performed in specialized centers in European and Far Eastern countries[15,23-25,43,55].Subtotal gastrectomy can also be performed in patient with gastric cancer arising in the middle part of the stomach, as the length of proximal resection margin is currently the single most important factor in deciding the final gastric resection extent[33,72]. Although total gastrectomy was recommended in the past as the standard surgery for middle-third gastric cancer, it has been shown that subtotal gastrectomy can be carried out in middle-third gastric cancer patients when a 3-6 cm tumor proximal free margin can be achieved, according to the Lauren histological type[33]. In early gastric cancer, subtotal gastrectomy is the gold standard treatment, whereas in case of advanced gastric cancer, the intraoperative frozen section histopatological evaluation of the transection line is useful to detect positive margins and proceed to total gastrectomy. Other more recent studies supported this stomach spearing strategy in the treatment of gastric cancer located in the middle third. Subtotal gastrectomy was performed in 39.3% of the 402 patients with middle-third advanced gastric cancer at the Korea University College in Seoul, compared to 83.3% of the 172 patients with lower-third cancer80]. In this study, as expected, the patients who underwent total gastrectomy had more advanced T stage; however, there was no difference in stage-stratified survival rate based on the extent of curative gastric resection. Multivariate analysis revealed that the type of gastric resection and the length of the proximal resection margin, using cut-off value from 1-5 cm in intervals of 1 cm, had no impact on 5-years survival. Similar results were reported in another study from the same region[81]. In order to prevent local recurrence of cancer, a > 6.5 cm gross margin was recommended in the past82]. More recently, >3 cm a margin in the final pathology for advanced gastric cancer has been considered adequate. However, according to the Japanese Classification of Gastric Cancer Carcinoma (2nd English Edition) high chances of cure are achieved when the resection margin is > 1 cm. The resection line infiltration is an unfavorable prognostic factor at any stage of the disease, and patients in good general condition for whom radical surgery is possible should be considered for reoperation[51]. Since long-term oncologic outcome does not seem to be affected by the type of gastric resection, nor by the length of the proximal resection margin, patients with middle-third advanced gastric cancer can be safely treated with subtotal gastrectomy with curative intent. Such patients will benefit in terms of postoperative morbidity and mortality rates, as well as quality of life.

***“Two thirds” of “four fifth” subtotal gastrectomy and the destiny of the left gastric artery***

The extent of gastric resection is usually defined as “two thirds” or “four fifths” of the stomach. From an oncological standpoint, this is not relevant, provided that the proximal margin of the resection falls in healthy tissue and adequate lymph node dissection is performed; however, the size of the remnant stomach is important for the reconstruction phase following partial gastrectomy. If the gastric stump is too short, reconstruction is preferably done by using Billroth II or Roux-en-Y methods. The Billroth I method can be performed when the size of the remaining stomach allows obtaining a tension-free gastroduodenal anastomosis. In addition, the length of the gastric remnant may cause concern about the vascularization of the distal end of the gastric stump. The extensive resection and LN dissection disrupting the arterial branches surrounding the stomach, including LN station #1, that provide the blood supply to the gastric stump, may contribute to postoperative necrosis of the distal part of the gastric stump and unfavorable outcome. After standard D2 subtotal gastrectomy for advanced gastric cancer, the blood supply of the gastric stump is maintained up to the level of resection by the esophagocardiotuberal branches and the short gastric arteries. However, the gastric stump might show poor vascularization in the resection area if the stump is too long, thus entailing possible risk of late ischemia not detected during operation, and postoperative fistula at the gastroduodenal or gastrojejunal anastomosis. Hence, when the left gastric artery is divided at the root from the celiac trunk and radical lymphatic clearance is performed, the short gastric vessels should be preserved and a “four fifth” subtotal gastrectomy performed; the type of reconstruction will depend on the surgeon’s choice and on the remaining stomach length. In case of EGC without gross lymph node metastases, D1+β or D2 LN dissection can be performed with preservation of the left gastric artery and its “ascending branch”, especially if the tumor is distally located on the greater curvature[83]. In this setting, adequate LN dissection can be performed by skeletonizing the hepatic artery, the celiac trunk, and then the left gastric artery as in transplant surgery, by removing the adipose tissue containing the lymphatics along these arteries. Similarly, extended LN dissection can be carried out along the splenic artery by preserving the pancreatic tail and spleen. Only the stem of the left gastric artery and the “ascending branch” can be preserved as the feeding artery for the gastric remnant, by dividing the “descending branch” at the root84]. The blood supply provided by this artery to the gastric remnant allows safely performing two-third subtotal gastrectomy, thus making it possible to proceed to reconstruction by tension-free Billroth I anastomosis, after dividing the short gastric vessels.

**THE ROLE OF CONVENTIONAL SURGERY IN EARLY-STAGE GASTRIC CANCER *VS* MINIMALLY INVASIVE TECHNIQUES**

***Subtotal gastrectomy versus endoscopic resection***

Although gastrectomy with LN dissection is still the gold standard treatment for Early Gastric Cancer, endoscopic surgical techniques such as endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) have been proposed in selected patients as alternative treatments to maintain good quality of life[85-87]. Typically, EMR of large lesions require piecemeal resection. ESD is an alternative technique which enables en bloc resection. With this technique, LN dissection is not performed and regional lymph nodes remain untreated. Therefore, patient selection is mandatory and this conservative technique can only be proposed for patients with low risk of LN metastases. According to the Japanese gastric cancer treatment guidelines of the Japanese Gastric Cancer Association (2010, ver.3), EMR or ESD are indicated as the standard treatment for differentiated-type adenocarcinoma without ulcerative findings, whose depth of invasion is clinically diagnosed as T1a and with ≤ 2 cm diameter. This group of tumors show very low incidence of LN metastases. In a large study on 5265 patients who underwent gastrectomy with LN dissection for EGC, the incidence of LN invasion was observed in only 2.7% of mucosal cancers and 18.6% of EGC invading the submucosa[83]. None of the 1230 well differentiated intramucosal cancers with less than 30 mm diameter were associated with LN metastases. Other risk factors for LN metastases were lymphatic-vascular involvement, undifferentiated histological type, and tumor diameter larger than 30 mm. The endoscopic resection of tumors with the aforementioned features is under investigation, and those tumors are considered as expanded indication. In 1,091 submucosal invasive tumors, the incidence of LN metastases was 20.3%[85]. As for intramucosal cancer, the presence of LN metastases had significant correlation with tumor size larger than 30 mm, undifferentiated histological type, and lymphatic-vascular involvement. The incidence of LN metastases in patients negative for these three risk factors was 5.6%; the authors suggested that in such subset of patients, LN dissection may not be necessary, and EMR or ESD should be performed. However, these criteria are based on the full histological examination of the resected specimen. Therefore, it is of paramount importance that the EMR or ESD is technically well performed and the specimen fully examined. Resection is deemed curative when the tumor size is ≤ 2 cm and en-bloc resection with negative margins is performed for pT1a histologically differentiated-type without lymphovascular infiltration. When EMR or ESD is deemed non curative, additional surgical treatment should be recommended. Gastrectomy is also required when EMR or ESD are not feasible and, since most tumors are located in the middle and distal thirds of the stomach, subtotal gastrectomy with LN dissection remains the treatment of choice.

***Laparoscopic-assisted distal gastrectomy versus open procedure***

Laparoscopic surgery for gastric cancer has gained popularity since its first application in 1991[88]. With the improvement of laparoscopic instruments and laparoscopic techniques, minimally invasive surgery has recorded increasing clinical application to treat early-stage gastric cancer[89]. In Asian countries such as Japan and Korea, laparoscopic-assisted distal gastrectomy (LADG) has become a standard therapy for early gastric cancer (EGC) located in the distal and middle thirds[90,91]. Furthermore, the development of said technique entailed wide acceptance also for other type of gastrectomies. The results of a retrospective multicenter study carried out in Korea by the Korean Laparoscopic Gastrointestinal Surgery Study (KLASS) group, showed that laparoscopic-assisted gastrectomy (LAG) provided satisfactory long-term oncological outcomes, similar to those of open surgery[92]. In the above-mentioned study, indication for LAG were gastric cancer patients with preoperative stage Ia (cT1N0M0) diagnosis , except those who were suitable for endoscopic resection. However, as experience accumulated, indications were expanded to preoperative diagnosis of more advanced early-stage disease (cT1N1M0, cT2N0M0, and cT2N1M0). The incidence of recurrence was 1.6% (19/1186) in EGC and 13.4% (31/231) in advanced gastric cancer (AGC)[93]. The study suggests that LAG is a good alternative to open gastrectomy in patients with relatively early-stage gastric cancer. LAG has several significant advantages, including less intraoperative blood loss, less postoperative pain, earlier postoperative recovery, and shorter hospital stay. However, adequate lymphadenectomy represents the most important prognostic factor in gastric cancer, and the reliability of laparoscopic approach depends on performing D2 dissection correctly as in open surgery, following the criteria of the Japanese Gastric Cancer Association guidelines. It is estimated that laparoscopic approach is employed in about 20% of gastric cancer surgeries in Japan; nevertheless, according to the Japanese gastric cancer guidelines (2010, ver.3), this minimally invasive technique should be considered as an investigational treatment. At present, although the long-term results of the phase III KLASS trial are yet to be published, LAG is considered to be accepted for EGC[94]. In intramucosal cancer not suitable for endoscopic resection or after non-curative endoscopic resection, surgical treatment is recommended and the laparoscopic approach seems to be a good alternative to conventional open surgery, as a D1+β LN dissection can be safely performed with curative intent. The application of LAG for AGC remains controversial due to the technical difficulty of performing a complete D2 lymphadenectomy. Extended LN dissection was shown to be technically feasible with a high number of retrieved nodes in both laparoscopic and robotic approaches[95,96]. However, the preoperative diagnosis of AGS with obvious node metastases does not represent an indication for the minimally invasive approach. In several series, preoperative understaging of EGC conceals the presence of AGC in 4.6%-7.6% of cases. The retrospective analysis of the KLASS group regarding 239 patients who were diagnosed with AGC on final pathologic examination, showed that the long-term survival outcome rates were comparable to those previously reported for open gastrectomy[92]. In this study, a D2 LN dissection was performed in 68.2% of the procedures; however, only 23% of the patients were diagnosed with stage III or IV disease. A recent meta-analysis of LADG showed that the short-term outcome of LADG for EGC is better than that of the open procedure[97]. However, LADG was significantly less performing compared to open distal gastrectomy in terms of operative time, and also showed a smaller number of harvested lymph nodes. The long-term outcome should be proven by further results of ongoing randomized clinical trials.

***LADG technical aspects***

From a technical standpoint, several techniques have been described to perform minimally invasive distal gastrectomy, including laparoscopic-assisted and robotic-assisted techniques with extracorporeal anastomosis, which are the most frequently described ones - and the entirely intracorporeal technique. In the laparoscopic and robotic-assisted techniques, minilaparotomy is performed after mobilization of the stomach and division of the gastric vessels at the root together with LN dissection. The mobilized stomach is pulled out through the minilaparotomy site and resected. Billroth I or II, or Roux-en-Y anastomosis can be performed extracorporeally by using stapling devices or hand-sewing techniques, depending on the surgeon’s choice[98-100]. In addition, LN dissection of the nodes behind the hepatic artery or portal vein that are not easily harvested by laparoscopy, can be safely removed through this minilaparotomy before reconstruction. In entirely intracorporeal subtotal gastrectomy, side-to-side gastrojejunal anastomosis is usually performed using laparoscopic linear cutter staples through two access openings of the jejunal limb and the posterior wall of the gastric stump. Then, the openings are closed with running suture or extracorporeal slipknots, depending on surgeon’s preference[95]. Then, the resected stomach is extracted using a polyethylene endobag through the enlarged umbilical incision or, preferably, from a suprapubic incision. Since most of the tumors treated by LADG are EGC, and the tumor border is often unclear, preoperative endoscopic marking of the proximal margin of the tumor is recommended in order to obtain a proximal resection margin of at least 2 cm in pT1 tumors.

**RECONSTRUCTION AFTER DISTAL SUBTOTAL GASTRECTOMY AND LONG-TERM OUTCOME**

The extent of gastric resection does not influence survival when patients are matched for stage groups, and the type of reconstruction after SG for gastric cancer has never been associated with any prognostic value[15,24,40]. After subtotal gastrectomy, the following reconstruction methods are usually employed: Billroth I gastroduodenostomy, Billroth II gastrojejunostomy with or without Braun anastomosis, Roux-en-Y gastrojejunostomy,uncut Roux-en-Y gastrojejunostomy, and jejunal interposition. Distal subtotal gastrectomy entails risks of symptomatic gastrooesophageal reflux disease (GERD) and cancer of the gastric stump (CGS); however, in the past, the impact of partial gastrectomy for benign peptic disease on survival was found to be so weak that prophylactic endoscopic monitoring was unrewarded before 15 to 20 years postoperatively[101]. In Far Eastern countries, where the incidence of gastric cancer is high and subtotal gastrectomy is the most frequently performed procedure, all types of reconstructions are routinely performed depending on surgeon and/or Institution choice, and the Japanese Gastric Cancer Treatment Guidelines 2010 (ver.3) do not recommend any type of reconstruction after distal gastrectomy. Each type entails advantages and disadvantages. A choice should be based on personal experience and surgical results, as well as the functional outcome and postoperative quality of life. The most important factor influencing postoperative quality of life is symptomatic bile reflux esophagitis, and various reconstruction methods have been introduced in order to reduce bile reflux and prevent symptoms; however, this complication occurs in 5% of the patients, regardless of the type of reconstruction[102]. Billroth I and Billroth II reconstructions are the preferred method of anastomosis across Japan, whereas reconstruction using Roux-en-Y anastomosis is more common in Europe and North America, with a view topreventing GERD, reducing the risk of CGS, and improving the functional outcome[99,103-106]**.** However, there is no convincing evidence proving that one method is better than the other from both a carcinogenetic and functional standpoints[100,107-109]**.**

***Risk of cancer of the gastric stump***

The interval between subtotal gastrectomy for gastric cancer and detection of CGS is significantly shorter compared to previous gastrectomy for benign ulcer disease, with the first one being 5-10 years from primary operation, while the latter is more than 15-20 years[110.111]. CGS within 5 years from gastrectomy was shown to occur only in patients who had primary surgery for gastric cancer, even at an early stage; however, such early recurrence probably results from incorrect initial diagnosis of multicentric disease or from non-curative initial gastrectomy. Unfortunately, such type of recurrences may occur despite accurate pre- and intraoperatively patient selection, and they are not related to the type of reconstruction; they are rather due to the surgical choice to perform partial gastrectomy instead of total gastrectomy. On the other hand, true primary CGS occurs later, more than 5 years after operation, and can result from the same pathogenetic pathway that leads to CGS after resection for benign disease, where the role of reflux and type of reconstruction remain controversial. The incidence of true primary CGS is less than 1% on the long term[15,111,112]. In Far-Eastern countries, surgeons adopted a radical approach to lymph node dissection but not to the extent of gastric resection, and SG accounts for two thirds of all cancer gastrectomies, with early carcinoma affecting 60 per cent of all patients[15,113]. In Japan, CGS was observed after both Billroth I and Billroth II procedures, but also after Roux-en-Y procedure[110,111,114,115], and the type of reconstruction after SG has never been recognized as being a prognostic factor. In our previous study, the incidence of CGS after Billroth I SG was 0.7% in the very long term[112]. Therefore, the impact of the type of reconstruction on CGS development remains most theoretical than practical. The theoretical 1% long -term risk of CGS does not justify “*en principe*” TG, even in young patients with long-term life expectancy, unless they have a history of familial gastric cancer. In our previous study, SG in young patients with favourable pathological staging was confirmed to improve long-term survival and have favourable functional outcome[116]. However, lifelong endoscopic monitoring is recommended after initial gastrectomy for all patients, especially those operated at an early stage, because early diagnosis of CGS entails hope for cure[111,115,117].

***Functional outcome***

Postoperative quality of life is an important goal when treating gastric cancer surgically. After partial gastrectomy, some patients report disorders such as reflux esophagitis and alkaline gastritis, but also dumping syndrome, delayed gastric emptying, and malabsorption, which are defined as functional dyspepsia. Duodeno-gastric reflux has been recognized to be a major cause of clinical symptoms after resection. 5 per cent incidence of functional failure (Visick grade of III or IV)[117] has been reported after all different types of reconstructions but symptoms are not always correlated with reflux disease[102,104,113,119]. Our previous study on the functional outcome after Billroth I SG showed that functional failure is not only related to reflux disease, but also to functional dyspepsia that is a multifactorial disorder[112]. Bile reflux into the gastric remnant following Billroth I and II reconstruction has been reported to be a frequent event. The endoscopic evidence of bile reflux or chronic superficial gastritis is not directly correlated with symptoms, and the latter may be similar to those shown by healthy subjects. The conclusions of several studies comparing the functional outcome of the different reconstructive procedures remains controversial101,103-109]. Roux-Y reconstruction seems to be effective in reducing bile reflux into the stomach, compared to Billroth I and II procedure[100,103,106], and conversion to this procedure has been reported in patients with symptomatic uncontrolled reflux disease. However, other studies showed limited benefits from Roux-Y over Billroth I or II anastomosis, because of frequent complications including Roux-Y stasis syndrome or gallstones formation, and they failed to demonstrate that there is any significant difference in the long-term postoperative functional outcome[104,105,107-109,120]. A large study on the endoscopic evaluation of the remnant stomach failed to find significant long-term difference in terms of bile reflux for the three types of reconstructions, and confirmed that only reflux esophagitis is the real gold standard for symptomatic reflux disease[102]; endoscopy showed that only a minority of the patients (less than 5%), reported signs of reflux oesophagitis, independent of the type of partial gastrectomy, thus confirming that other functional disorders, such as the decrease in lower oesophageal sphincter pressure, the presence of a hiatus hernia, or the accommodation of the remnant stomach to a meal, can lead to post-gastrectomy functional dyspepsia. In our previous study on the very long-term functional outcome of Billroth I SG followed up to 18 years, we found encouraging results in terms of absence of meal-related discomfort, normal number of meals per day, and we were surprised to record that the majority of our patients had completely recovered from surgery and they could hardly see any difference compared to their preoperative conditions[112]. Postoperative endoscopy showed no evidence of mucosal changes in 85 per cent of patients, including those who had been operated more than 10 years before. Similar results have been reported for the other type of reconstructions[100,106,109].

**FOLLOW-UP**

Pre- and intraoperative accurate patient selection remains mandatory, and this procedure can be considered as a valid option in patients with favourable pathological staging. After resection, no specific diagnostic method has been identified to detect recurrence. Recurrence is usually diagnosed through a combination of exams, including ultrasound, computed tomography, positron emission tomography, and tumour marker evaluation. Computed tomography seems to be essential in the follow-up of patients. Consensus has not been reached as to the optimal frequency; it is usually performed every 3 to 12 months, depending on the stage of the disease and time elapsed since surgery. Furthermore, after subtotal gastrectomy, lifelong endoscopic monitoring is recommended to detect possible mucosal changes at an early stage.

**COST-EFFECTIVENESS**

The clinical research that has been carried out in the last thirty years was promoted with a view to defining the clinical benefits of subtotal gastrectomy compared to total gastrectomy, in terms of quality of life, including nutritional status, functional dyspepsia, and long term survival. Moreover, it has placed special focus on gastric stump recurrence. In the last decade, new studies have been conducted comparing open conventional distal gastrectomy with the laparoscopic approach or endoscopic resection in case of EGC, and other studies compared conventional postoperative care with the fast-track program[94,121-123]. However, the main focus of such studies was placed on the clinical outcome and long-term results and, although these novel approaches are still considered as investigational according to the Japanese Gastric Cancer Treatment Guidelines 2010 (ver.3), their clinical applications are gaining more and more popularity among specialized surgeons. Little is known about the cost-effectiveness of subtotal gastrectomy for gastric cancer. The cost-effectiveness of the procedures is yet to be calculated, and no specific information can be provided, as multiple and different variables contribute to the cost-analysis of such an intriguing surgical procedure and its variants, including the social organization and the health system of each individual Country. In particular, the phase III controlled randomized multicenter KLASS 01 trial carried out in Korea on 1415 patients, included cost-effectiveness among its secondary endpoints[124]. However, the trial is currently ongoing and the cost analysis is still being conducted.

The cost-effectiveness analysis focused mainly on primary and secondary preventive strategies, and on postoperative adjuvant chemotherapies for resectable gastric cancer. *H. pylori* infection is estimated to carry a significant lifetime risk of developing peptic ulcer and gastric cancer. Screening the population for the presence of *H. pylori* infection and treating *H. pylori*-positive subjects may reduce mortality and morbidity in the future decades[125]. The serology screening and 13C-urea breath test for *H. pylori* were shown to achieve more health benefit at a lower cost compared to no screening in the Chinese population. The serology screening was found to be cost- effective[126]. A well designed study on a limited and controlled population in Taiwan showed that a once-only chemoprevention program should initiateearlier in life, and suggested that primary prevention dominates on secondary prevention strategy for high risk groups[127]. *H. pylori* eradication at an early stage can effectively ameliorate the infiltration of acute inflammatory cells and protect the gastric mucosa from irreversible damage. Early-stage gastric cancer detection in the secondary prevention strategy represents a critical issue in improving prognosis. Endoscopic screening of the population for gastric cancer is generally deemed not to be cost effective, except in Japan, where prevalence is very high. However, stomach screening in moderate to high-risk population subgroups was shown to be cost-effective[128]. Patients that are diagnosed with gastric cancer at an early stage are more likely to undergo partial gastrectomy than total gastrectomy, thus making moderate-high risk population screening results cost effective even from a surgical standpoint.

**CONCLUSION**

This article on subtotal gastrectomy for gastric cancer aimed to clarify the actual landmarks of this procedure and the role it plays compared to the whole range of new and old treatment methods. Since the clinical application of the study is very helpful for patient evaluation and decision making, we recommend the readers to apply this knowledge into routine clinical practice.

**REFERENCES**

1 **Parkin DM**, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. *Int J Cancer* 1993; **54**: 594-606 [PMID: 8514451 DOI: 10.1002/ijc.2910540413]

2 **Stewart BW,** Kleihues P. World Cancer Report. Lyon: IARC Press, 2003

3 **World Health Organization.** The world health report. Geneva WHO, 1997

4 **Muñoz N**, Correa P, Cuello C, Duque E. Histologic types of gastric carcinoma in high- and low-risk areas. *Int J Cancer* 1968; **3**: 809-818 [PMID: 5731983 DOI: 10.1002/ijc.2910030614]

5 **Lauren P**. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. *Acta Pathol Microbiol Scand* 1965; **64**: 31-49 [PMID: 14320675]

6 **Crew KD**, Neugut AI. Epidemiology of gastric cancer. *World J Gastroenterol* 2006; **12**: 354-362 [PMID: 16489633 DOI: 1007-9327/12/354.asp]

7 **Parkin DM**, Whelan SL, Ferlay J, Raymond L, Young J, editors. Cancer incidence in five continents. Vol 7. Lyon: IARC, 1997

8 **Billroth T.** Offenes Schreiben a Herrn Dr. L. Wittelshofer. *Wien Med Wochenschr* 1881; **31**: 161–165

9 **Schlatter K.** A unique case of complete removal of the stomach successful esophago-enterostomy recovery. *Med Rec* 1897; **52**: 909–914

10 **Macguire CJ**. SOME CLINICAL FINDINGS IN SUBTOTAL GASTRECTOMY. *Ann Surg* 1929; **89**: 658-668 [PMID: 17866093]

11 **Murakami E,** Nagatomo T, Hori K, Asano N, Shirai T. [Progress in studies on stomach cancer in Japan]. Nihon Rinsho 1967; **25**: 1513-1550 [PMID: 5626621]

12 **Japanese Research Society for Gastric Cancer.** Japanese classification of gastric carcinoma, First English ed. Tokyo: Kanehara Co., Ltd.; 1995

13 IARC Unit of Descriptive Epidemiology: WHO cancer mortality databank. *Cancer Mondial* 2001; 824-837

14 **Nakamura K**, Ueyama T, Yao T, Xuan ZX, Ambe K, Adachi Y, Yakeishi Y, Matsukuma A, Enjoji M. Pathology and prognosis of gastric carcinoma. Findings in 10000 patients who underwent primary gastrectomy. *Cancer* 1992; **70**: 1030-1037 [PMID: 1515980]

15 **Maruyama K**, Kaminishi M, Hayashi K, Isobe Y, Honda I, Katai H, Arai K, Kodera Y, Nashimoto A. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. *Gastric Cancer* 2006; **9**: 51-66 [PMID: 16767357 DOI: 10.1007/s10120-006-0370-y]

16 **Sano T**, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. *J Clin Oncol* 2004; **22**: 2767-2773 [PMID: 15199090 DOI: 10.1200/JCO.2004.10.184]

17 **Tepper SJ**. New thoughts on sinus headache. *Allergy Asthma Proc* 1992; **25**: 95-96 [PMID: 15176492 DOI: 10.1002/bjs.1800790404]

18 **Verdecchia A**, Corazziari I, Gatta G, Lisi D, Faivre J, Forman D. Explaining gastric cancer survival differences among European countries. *Int J Cancer* 2004; **109**: 737-741 [PMID: 14999783 DOI: 10.1002/ijc.20047]

19 **McNeer G**, Bowden L, Booner RJ, McPeak CJ. Elective total gastrectomy for cancer of the stomach: end results. *Ann Surg* 1974; **180**: 252-256 [PMID: 4601986]

20 **Lortat-Jacob J**, Giuli R, Estenne B, Clot P. [Value of total gastrectomy for treatment of cancers of the stomach. Study of 482 radical operations]. *Chirurgie* ; **101**: 59-67 [PMID: 1212895]

21 **Wanebo HJ**, Kennedy BJ, Chmiel J, Steele G, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. *Ann Surg* 1993; **218**: 583-592 [PMID: 8239772 DOI: 10.1097/00000658-199321850-00002]

22 **Heberer G**, Teichmann RK, Krämling HJ, Günther B. Results of gastric resection for carcinoma of the stomach: the European experience. *World J Surg* 1988; **12**: 374-381 [PMID: 3400248 DOI: 10.1007/BF01655678]

23 **Siewert JR**, Böttcher K, Roder JD, Busch R, Hermanek P, Meyer HJ. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. *Br J Surg* 1993; **80**: 1015-1018 [PMID: 8402053]

24 **Sánchez-Bueno F**, Garcia-Marcilla JA, Perez-Flores D, Pérez-Abad JM, Vicente R, Aranda F, Ramirez P, Parrilla P. Prognostic factors in a series of 297 patients with gastric adenocarcinoma undergoing surgical resection. *Br J Surg* 1998; **85**: 255-260 [PMID: 9501830 DOI: 10.1046/j.1365-2168.1998.00558.x]

25 **Santoro E**, Carlini M, Garofalo A, Carboni F, Santoro R, Castelli M. Gastric cancer. Clinico-biological updating and analysis of 400 operated cases. *J Exp Clin Cancer Res* 1998; **17**: 175-185 [PMID: 9700578]

26 **Zhang XF**, Huang CM, Lu HS, Wu XY, Wang C, Guang GX, Zhang JZ, Zheng CH. Surgical treatment and prognosis of gastric cancer in 2,613 patients. *World J Gastroenterol* 2004; **10**: 3405-3408 [PMID: 15526356 DOI: 1007-9327/10/3405.asp]

27 **Le Treut YP**, Echimane A, Hans D, Maillet B, Maurin B, Bricot R. [Cancer of the gastric antrum. What can be expected from the systematic enlargement of the excision? Retrospective study of 73 cases]. *Presse Med* 1985; **14**: 1319-122, 1327 [PMID: 3161021]

28 **Gennari L**, Bozzetti F, Bonfanti G, Morabito A, Bufalino R, Doci R, Andreola S. Subtotal versus total gastrectomy for cancer of the lower two-thirds of the stomach: a new approach to an old problem. *Br J Surg* 1986; **73**: 534-538 [PMID: 3730785 DOI: 10.1002/bjs.1800730706]

29 **Santoro E,** Garofalo A. Il cancro dello stomaco negli ospedali italiani. Rome: Edizioni Scientifiche Romane; 1988.

30 **Santoro E**, Garofalo A, Scutari F, Zanarini T, Carlini M, Santoro E. Early gastric cancer: total gastrectomy vs. distal resection. Results of a study of 271 cases. The Italian Stomach Cancer Group (A.C.O.I.-I.S.C.G.). *Hepatogastroenterology* 1991; **38**: 427-429 [PMID: 1765361]

31 **Launois B**, Cardin JL, Bardaxoglou E, Bourdonnec P, de Chateaubriant P, Buard JL, Campion JP. Management of cancer of the stomach: total gastrectomy versus sub-total gastrectomy. *Hepatogastroenterology* 1991; **38**: 45-52 [PMID: 2026388]

32 **Gouzi JL**, Huguier M, Fagniez PL, Launois B, Flamant Y, Lacaine F, Paquet JC, Hay JM. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. *Ann Surg* 1989; **209**: 162-166 [PMID: 2644898 DOI: 10.1097/00000658-198902000-00005]

33 **Bozzetti F**, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. *Ann Surg* 1999; **230**: 170-178 [PMID: 10450730 DOI: 10.1097/00000658-199908000-00006]

34 **Maruyama K**, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. *World J Surg* 1987; **11**: 418-425 [PMID: 3630186 DOI: 10.1007/BF01655804]

35 **Maruyama K**, Gunvén P, Okabayashi K, Sasako M, Kinoshita T. Lymph node metastases of gastric cancer. General pattern in 1931 patients. *Ann Surg* 1989; **210**: 596-602 [PMID: 2818028 DOI: 10.1097/00000658-198911000-00005]

36 **Bonenkamp JJ**, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, van Elk P, Obertop H, Gouma DJ, Taat CW. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. *Lancet* 1995; **345**: 745-748 [PMID: 7891484 DOI: 10.1016/S0140-6736(95)90637-1]

37 **Bonenkamp JJ**, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, Meyer S, Plukker JT, Van Elk P, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H. Extended lymph-node dissection for gastric cancer. *N Engl J Med* 1999; **340**: 908-914 [PMID: 10089184 DOI: 10.1056/NEJM199903253401202]

38 **Cuschieri A**, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. *Br J Cancer* 1999; **79**: 1522-1530 [PMID: 10188901 DOI: 10.1038/sj.bjc.6690243]

39 **Hartgrink HH**, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, Welvaart K, van Krieken JH, Meijer S, Plukker JT, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. *J Clin Oncol* 2004; **22**: 2069-2077 [PMID: 15082726 DOI: 10.1200/JCO.2004.08.026]

40 **Siewert JR**, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. *Ann Surg* 1998; **228**: 449-461 [PMID: 9790335 DOI: 10.1097/00000658-199810000-00002]

41 **Songun I**, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. *Lancet Oncol* 2010; **11**: 439-449 [PMID: 20409751 DOI: 10.1016/S1470-2045(10)70070-X]

42 **Sasako M**, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. *N Engl J Med* 2008; **359**: 453-462 [PMID: 18669424 DOI: 10.1056/NEJMoa0707035]

43 **Park CH**, Song KY, Kim SN. Treatment results for gastric cancer surgery: 12 years' experience at a single institute in Korea. *Eur J Surg Oncol* 2008; **34**: 36-41 [PMID: 17442532 DOI: 10.1016/j.ejso.2007.03.004]

44 **Japanese Gastric Cancer Association.** Japanese Classification of Gastric Carcinoma-2nd English Edition. *Gastric Cancer* 1998; **1**: 10-24 [PMID: 11957040]

45 **Japanese Gastric Cancer Association.** Japanese Gastric Cancer Treatment Guidelines 2010 (ver. 3). *Gastric Cancer* 2011; **14**: 113-123 [PMID: 21573742 DOI: 10.1007/s10120-011-0042-4]

46 **Santoro E,** Garofalo A. Il cancro dello stomaco negli ospedali italiani. Vol V. Rome: Edizioni Scientifiche Romane; 1996

47 **Adachi Y**, Suematsu T, Shiraishi N, Tanimura H, Morimoto A, Kitano S. Perigastric lymph node status as a prognostic indicator in patients with gastric cancer. *Br J Surg* 1998; **85**: 1281-1284 [PMID: 9752878 DOI: 10.1046/j.1365-2168.1998.00833.x]

48 **Fujii K**, Isozaki H, Okajima K, Nomura E, Niki M, Sako S, Izumi N, Mabuchi H, Nishiguchi K, Tanigawa N. Clinical evaluation of lymph node metastasis in gastric cancer defined by the fifth edition of the TNM classification in comparison with the Japanese system. *Br J Surg* 1999; **86**: 685-689 [PMID: 10361195 DOI: 10.1046/j.1365-2168.1999.01115.x]

49 **Karpeh MS**, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. *Ann Surg* 2000; **232**: 362-371 [PMID: 10973386 DOI: 10.1097/00000658-200009000-00008]

50 **Spanknebel KA**, Brennan MF. Is D2 lymphadenectomy for gastric cancer a staging tool or a therapeutic intervention? *Surg Oncol Clin N Am* 2002; **11**: 415-30, xii [PMID: 12424860 DOI: 10.1016/S1055-3207(02)00008-X]

51 **Morgagni P**, Garcea D, Marrelli D, De Manzoni G, Natalini G, Kurihara H, Marchet A, Saragoni L, Scarpi E, Pedrazzani C, Di Leo A, De Santis F, Panizzo V, Nitti D, Roviello F. Resection line involvement after gastric cancer surgery: clinical outcome in nonsurgically retreated patients. *World J Surg* 2008; **32**: 2661-2667 [PMID: 18825453 DOI: 10.1007/s00268-008-9747-x]

52 **Lewis FR**, Mellinger JD, Hayashi A, Lorelli D, Monaghan KG, Carneiro F, Huntsman DG, Jackson CE, Caldas C. Prophylactic total gastrectomy for familial gastric cancer. *Surgery* 2001; **130**: 612-67; discussion 612-67; [PMID: 11602891 DOI: 10.1067/msy.2001.117099]

53 **Pandalai PK**, Lauwers GY, Chung DC, Patel D, Yoon SS. Prophylactic total gastrectomy for individuals with germline CDH1 mutation. *Surgery* 2011; **149**: 347-355 [PMID: 20719348 DOI: 10.1016/j.surg.2010.07.005.]

54 **Sasako M**, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. *Br J Surg* 1995; **82**: 346-351 [PMID: 7796005 DOI: 10.1002/bjs.1800820321]

55 **Kim JP**, Lee JH, Kim SJ, Yu HJ, Yang HK. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. *Gastric Cancer* 1998; **1**: 125-133 [PMID: 11957056 DOI: 10.1007/s101200050006]

56 **Pacelli F**, Doglietto GB, Bellantone R, Alfieri S, Sgadari A, Crucitti F. Extensive versus limited lymph node dissection for gastric cancer: a comparative study of 320 patients. *Br J Surg* 1993; **80**: 1153-1156 [PMID: 8402119 DOI: 10.1002/bjs.1800800930]

57 **de Manzoni G**, Verlato G, Guglielmi A, Laterza E, Genna M, Cordiano C. Prognostic significance of lymph node dissection in gastric cancer. *Br J Surg* 1996; **83**: 1604-1607 [PMID: 9014687 DOI: 10.1002/bjs.1800831137]

58 **Marchet A**, Mocellin S, Ambrosi A, Morgagni P, Garcea D, Marrelli D, Roviello F, de Manzoni G, Minicozzi A, Natalini G, De Santis F, Baiocchi L, Coniglio A, Nitti D. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. *Ann Surg* 2007; **245**: 543-552 [PMID: 17414602 DOI: 10.1097/01.sla.0000250423.43436.e1]

59 **Edge SB,** Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Spinger-Verlag; 2010

60 **International Union Against Cancer.** In: Sobin LH, Gos-podarowicz, MK, Wittekind C, editors. TNM classification of malignant tumours. 7th ed. New Jersey: Wiley-Blackwell; 2009.

61 **Arai T**, Esaki Y, Inoshita N, Sawabe M, Kasahara I, Kuroiwa K, Honma N, Takubo K. Pathologic characteristics of gastric cancer in the elderly: a retrospective study of 994 surgical patients. *Gastric Cancer* 2004; **7**: 154-159 [PMID: 15449203 DOI: 10.1007/s10120-004-0285-4]

62 **Kong SH**, Yoo MW, Kim JW, Lee HJ, Kim WH, Lee KU, Yang HK. Validation of limited lymphadenectomy for lower-third gastric cancer based on depth of tumour invasion. *Br J Surg* 2011; **98**: 65-72 [PMID: 20954197 DOI: 10.1002/bjs.7266]

63 **Yasuda K**, Shiraishi N, Suematsu T, Yamaguchi K, Adachi Y, Kitano S. Rate of detection of lymph node metastasis is correlated with the depth of submucosal invasion in early stage gastric carcinoma. *Cancer* 1999; **85**: 2119-2123 [PMID: 10326688 DOI: 10.1002/(SICI)1097-0142(19990515)85: 10<2119: : AID-CNCR4>3.0.CO; 2-M]

64 **Morgagni P**, Saragoni L, Folli S, Gaudio M, Scarpi E, Bazzocchi F, Marra GA, Vio A. Lymph node micrometastases in patients with early gastric cancer: experience with 139 patients. *Ann Surg Oncol* 2001; **8**: 170-174 [PMID: 11258783 DOI: 10.1245/aso.2001.8.2.170]

65 **Nakajo A**, Natsugoe S, Ishigami S, Matsumoto M, Nakashima S, Hokita S, Baba M, Takao S, Aikou T. Detection and prediction of micrometastasis in the lymph nodes of patients with pN0 gastric cancer. *Ann Surg Oncol* 2001; **8**: 158-162 [PMID: 11258781 DOI: 10.1245/aso.2001.8.2.158]

66 **Carlini M**, Carboni F, Petric M, Santoro R, Guadagni F, Marandino F, Castelli M, Santoro E. Sentinel node in gastric cancer surgery. *J Exp Clin Cancer Res* 2002; **21**: 469-473 [PMID: 12636091]

67 **Kitagawa Y**, Takeuchi H, Takagi Y, Natsugoe S, Terashima M, Murakami N, Fujimura T, Tsujimoto H, Hayashi H, Yoshimizu N, Takagane A, Mohri Y, Nabeshima K, Uenosono Y, Kinami S, Sakamoto J, Morita S, Aikou T, Miwa K, Kitajima M. Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan. *J Clin Oncol* 2013; **31**: 3704-3710 [PMID: 24019550 DOI: 10.1200/JCO.2013.50.3789]

68 **Degiuli M**, Sasako M, Ponti A, Calvo F. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. *Br J Cancer* 2004; **90**: 1727-1732 [PMID: 15150592 DOI: 10.1038/sj.bjc.6601761]

69 **Roviello F**, Marrelli D, Morgagni P, de Manzoni G, Di Leo A, Vindigni C, Saragoni L, Tomezzoli A, Kurihara H. Survival benefit of extended D2 lymphadenectomy in gastric cancer with involvement of second level lymph nodes: a longitudinal multicenter study. *Ann Surg Oncol* 2002; **9**: 894-900 [PMID: 12417512 DOI: 10.1007/BF02557527]

70 **Seevaratnam R**, Bocicariu A, Cardoso R, Mahar A, Kiss A, Helyer L, Law C, Coburn N. A meta-analysis of D1 versus D2 lymph node dissection. *Gastric Cancer* 2012; **15** Suppl 1: S60-S69 [PMID: 22138927 DOI: 10.1007/s10120-011-0110-9]

71 **Wanebo HJ**, Kennedy BJ, Winchester DP, Fremgen A, Stewart AK. Gastric carcinoma: does lymph node dissection alter survival? *J Am Coll Surg* 1996; **183**: 616-624 [PMID: 8957465]

72 **De Manzoni G**, Verlato G, Roviello F, Di Leo A, Marrelli D, Morgagni P, Pasini F, Saragoni L, Tomezzoli A. Subtotal versus total gastrectomy for T3 adenocarcinoma of the antrum. *Gastric Cancer* 2003; **6**: 237-242 [PMID: 14716518 DOI: 10.1007/s10120-003-0261-4]

73 **Hundahl SA**, Macdonald JS, Benedetti J, Fitzsimmons T. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. *Ann Surg Oncol* 2002; **9**: 278-286 [PMID: 11923135 DOI: 10.1007/BF02573066]

74 **Smalley SR**, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. *J Clin Oncol* 2012; **30**: 2327-2333 [PMID: 22585691 DOI: 10.1200/JCO.2011.36.7136]

75 **Douglass HO**, Hundahl SA, Macdonald JS, Khatri VP. Gastric cancer: D2 dissection or low Maruyama Index-based surgery--a debate. *Surg Oncol Clin N Am* 2007; **16**: 133-155 [PMID: 17336241 DOI: 10.1016/j.soc.2006.10.005]

76 **Kampschöer GH**, Maruyama K, van de Velde CJ, Sasako M, Kinoshita T, Okabayashi K. Computer analysis in making preoperative decisions: a rational approach to lymph node dissection in gastric cancer patients. *Br J Surg* 1989; **76**: 905-908 [PMID: 2804584 DOI: 10.1002/bjs.1800760910]

77 **Bollschweiler E**, Boettcher K, Hoelscher AH, Sasako M, Kinoshita T, Maruyama K, Siewert JR. Preoperative assessment of lymph node metastases in patients with gastric cancer: evaluation of the Maruyama computer program. *Br J Surg* 1992; **79**: 156-160 [PMID: 1555065 DOI: 10.1002/bjs.1800790221]

78 **Guadagni S**, de Manzoni G, Catarci M, Valenti M, Amicucci G, De Bernardinis G, Cordiano C, Carboni M, Maruyama K. Evaluation of the Maruyama computer program accuracy for preoperative estimation of lymph node metastases from gastric cancer. *World J Surg* 2000; **24**: 1550-1558 [PMID: 11193722 DOI: 10.1007/s002680010276]

79 **Peeters KC**, Hundahl SA, Kranenbarg EK, Hartgrink H, van de Velde CJ. Low Maruyama index surgery for gastric cancer: blinded reanalysis of the Dutch D1-D2 trial. *World J Surg* 2005; **29**: 1576-1584 [PMID: 16317484 DOI: 10.1007/s00268-005-7907-9]

80 **Jang YJ**, Park MS, Kim JH, Park SS, Park SH, Kim SJ, Kim CS, Mok YJ. Advanced gastric cancer in the middle one-third of the stomach: Should surgeons perform total gastrectomy? *J Surg Oncol* 2010; **101**: 451-456 [PMID: 19924722 DOI: 10.1002/jso.21431]

81 **Lee JH**, Kim YI. Which Is the Optimal Extent of Resection in Middle Third Gastric Cancer between Total Gastrectomy and Subtotal Gastrectomy? *J Gastric Cancer* 2010; **10**: 226-233 [PMID: 22076190 DOI: 10.5230/jgc.2010.10.4.226]

82 **Papachristou DN**, Fortner JG. Local recurrence of gastric adenocarcinomas after gastrectomy. *J Surg Oncol* 1981; **18**: 47-53 [PMID: 7289619 DOI: 10.1002/jso.2930180108]

83 **Gotoda T**, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, Kato Y. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. *Gastric Cancer* 2000; **3**: 219-225 [PMID: 11984739 DOI: 10.1007/PL00011720]

84 **Hagiwara A**, Imanishi T, Sakakura C, Otsuji E, Kitamura K, Itoi H, Yamagishi H. Subtotal gastrectomy for cancer located in the greater curvature of the middle stomach with prevention of the left gastric artery. *Am J Surg* 2002; **183**: 692-696 [PMID: 12095603 DOI: 10.1016/S0002-9610(02)00854-1]

85 **Gotoda T**, Sasako M, Ono H, Katai H, Sano T, Shimoda T. Evaluation of the necessity for gastrectomy with lymph node dissection for patients with submucosal invasive gastric cancer. *Br J Surg* 2001; **88**: 444-449 [PMID: 11260114 DOI: 10.1046/j.1365-2168.2001.01725.x]

86 **Catalano F**, Trecca A, Rodella L, Lombardo F, Tomezzoli A, Battista S, Silano M, Gaj F, de Manzoni G. The modern treatment of early gastric cancer: our experience in an Italian cohort. *Surg Endosc* 2009; **23**: 1581-1586 [PMID: 19263148 DOI: 10.1007/s00464-009-0350-5]

87 **Ohkuwa M**, Hosokawa K, Boku N, Ohtu A, Tajiri H, Yoshida S. New endoscopic treatment for intramucosal gastric tumors using an insulated-tip diathermic knife. *Endoscopy* 2001; **33**: 221-226 [PMID: 11293753 DOI: 10.1055/s-2001-12805]

88 **Kitano S**, Iso Y, Moriyama M, Sugimachi K. Laparoscopy-assisted Billroth I gastrectomy. *Surg Laparosc Endosc* 1994; **4**: 146-148 [PMID: 8180768 DOI: 10.1097-00129689-200206000-00021]

89 **Carboni F**, Lepiane P, Santoro R, Mancini P, Lorusso R, Santoro E. Laparoscopic surgery for gastric cancer: preliminary experience. *Gastric Cancer* 2005; **8**: 75-77 [PMID: 15864713 DOI: 10.1007/s10120-005-0322-y]

90 **Kitano S**, Shiraishi N, Uyama I, Sugihara K, Tanigawa N. A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan. *Ann Surg* 2007; **245**: 68-72 [PMID: 17197967 DOI: 10.1097/01.sla.0000225364.03133.f8]

91 **Kim KH**, Kim MC, Jung GJ, Kim HH. Long-term outcomes and feasibility with laparoscopy-assisted gastrectomy for gastric cancer. *J Gastric Cancer* 2012; **12**: 18-25 [PMID: 22500260 DOI: 10.5230/jgc.2012.12.1.18]

92 **Park do J**, Han SU, Hyung WJ, Kim MC, Kim W, Ryu SY, Ryu SW, Song KY, Lee HJ, Cho GS, Kim HH. Long-term outcomes after laparoscopy-assisted gastrectomy for advanced gastric cancer: a large-scale multicenter retrospective study. *Surg Endosc* 2012; **26**: 1548-1553 [PMID: 22170319 DOI: 10.1007/s00464-011-2065-7]

93 **Song J**, Lee HJ, Cho GS, Han SU, Kim MC, Ryu SW, Kim W, Song KY, Kim HH, Hyung WJ. Recurrence following laparoscopy-assisted gastrectomy for gastric cancer: a multicenter retrospective analysis of 1,417 patients. *Ann Surg Oncol* 2010; **17**: 1777-1786 [PMID: 20151217 DOI: 10.1245/s10434-010-0932-4]

94 **Kim HH**, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, Ryu SW, Lee HJ, Song KY. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial). *Ann Surg* 2010; **251**: 417-420 [PMID: 20160637 DOI: 10.1097/SLA.0b013e3181cc8f6b]

95 **Pugliese R**, Maggioni D, Sansonna F, Costanzi A, Ferrari GC, Di Lernia S, Magistro C, De Martini P, Pugliese F. Subtotal gastrectomy with D2 dissection by minimally invasive surgery for distal adenocarcinoma of the stomach: results and 5-year survival. *Surg Endosc* 2010; **24**: 2594-2602 [PMID: 20414682 DOI: 10.1007/s00464-010-1014-1]

96 **Song J**, Oh SJ, Kang WH, Hyung WJ, Choi SH, Noh SH. Robot-assisted gastrectomy with lymph node dissection for gastric cancer: lessons learned from an initial 100 consecutive procedures. *Ann Surg* 2009; **249**: 927-932 [PMID: 19474671 DOI: 10.1097/01.sla.0000351688.64999.73]

97 **Zeng YK**, Yang ZL, Peng JS, Lin HS, Cai L. Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: evidence from randomized and nonrandomized clinical trials. *Ann Surg* 2012; **256**: 39-52 [PMID: 22664559 DOI: 10.1097/SLA.0b013e3182583e2e]

98 **Adachi Y**, Shiraishi N, Shiromizu A, Bandoh T, Aramaki M, Kitano S. Laparoscopy-assisted Billroth I gastrectomy compared with conventional open gastrectomy. *Arch Surg* 2000; **135**: 806-810 [PMID: 10896374 DOI: 10.1001/archsurg.135.7.806]

99 **Kojima K**, Yamada H, Inokuchi M, Kawano T, Sugihara K. A comparison of Roux-en-Y and Billroth-I reconstruction after laparoscopy-assisted distal gastrectomy. *Ann Surg* 2008; **247**: 962-967 [PMID: 18520223 DOI: 10.1097/SLA.0b013e31816d9526]

100 **Lee MS**, Ahn SH, Lee JH, Park do J, Lee HJ, Kim HH, Yang HK, Kim N, Lee WW. What is the best reconstruction method after distal gastrectomy for gastric cancer? *Surg Endosc* 2012; **26**: 1539-1547 [PMID: 22179454 DOI: 10.1007/s00464-011-2064-8]

101 **Bassily R**, Smallwood RA, Crotty B. Risk of gastric cancer is not increased after partial gastrectomy. *J Gastroenterol Hepatol* 2000; **15**: 762-765 [PMID: 10937681 DOI: 10.1046/j.1440-1746.2000.02203.x]

102 **Loffeld RJ**. Reflux esophagitis in patients with partial gastrectomy and Billroth I or II reconstruction. *Eur J Intern Med* 2006; **17**: 175-178 [PMID: 16618449 DOI: 10.1016/j.ejim.2005.11.009]

103 **Fukuhara K**, Osugi H, Takada N, Takemura M, Higashino M, Kinoshita H. Reconstructive procedure after distal gastrectomy for gastric cancer that best prevents duodenogastroesophageal reflux. *World J Surg* 2002; **26**: 1452-1457 [PMID: 12370787 DOI: 10.1007/s00268-002-6363-z]

104 **Nunobe S**, Okaro A, Sasako M, Saka M, Fukagawa T, Katai H, Sano T. Billroth 1 versus Roux-en-Y reconstructions: a quality-of-life survey at 5 years. *Int J Clin Oncol* 2007; **12**: 433-439 [PMID: 18071862 DOI: 10.1007/s10147-007-0706-6]

105 **Zong L**, Chen P. Billroth I vs. Billroth II vs. Roux-en-Y following distal gastrectomy: a meta-analysis based on 15 studies. *Hepatogastroenterology* 2011; **58**: 1413-1424 [PMID: 21937419 DOI: 10.5754/hge10567]

106 **Inokuchi M**, Kojima K, Yamada H, Kato K, Hayashi M, Motoyama K, Sugihara K. Long-term outcomes of Roux-en-Y and Billroth-I reconstruction after laparoscopic distal gastrectomy. *Gastric Cancer* 2013; **16**: 67-73 [PMID: 22467062 DOI: 10.1007/s10120-012-0154-5]

107 **Ishikawa M**, Kitayama J, Kaizaki S, Nakayama H, Ishigami H, Fujii S, Suzuki H, Inoue T, Sako A, Asakage M, Yamashita H, Hatono K, Nagawa H. Prospective randomized trial comparing Billroth I and Roux-en-Y procedures after distal gastrectomy for gastric carcinoma. *World J Surg* 2005; **29**: 1415-120; discussion 1421 [PMID: 16240061 DOI: 10.1007/s00268-005-7830-0]

108 **Tanaka S,** Matsuo K, Matsumoto H, Maki T, Nakano M, Sasaki T, Yamashita Y. Clinical outcomes of Roux-en-Y and Billroth I reconstruction after a distal gastrectomy for gastric cancer: What is the optimal reconstructive procedure? *Hepatogastroenterology* 2011; **58**: 257-262 [PMID:21510325]

109 **Imamura H**, Takiguchi S, Yamamoto K, Hirao M, Fujita J, Miyashiro I, Kurokawa Y, Fujiwara Y, Mori M, Doki Y. Morbidity and mortality results from a prospective randomized controlled trial comparing Billroth I and Roux-en-Y reconstructive procedures after distal gastrectomy for gastric cancer. *World J Surg* 2012; **36**: 632-637 [PMID: 22270979 DOI: 10.1007/s00268-011-1408-9]

110 **Takeno S**, Noguchi T, Kimura Y, Fujiwara S, Kubo N, Kawahara K. Early and late gastric cancer arising in the remnant stomach after distal gastrectomy. *Eur J Surg Oncol* 2006; **32**: 1191-1194 [PMID: 16797159 DOI: 10.1016/j.ejso.2006.04.018]

111 **Ohashi M**, Katai H, Fukagawa T, Gotoda T, Sano T, Sasako M. Cancer of the gastric stump following distal gastrectomy for cancer. *Br J Surg* 2007; **94**: 92-95 [PMID: 17054314 DOI: 10.1002/bjs.5538]

112 **Santoro R,** Mancini P, Carboni F, Lepiane P, Ettorre GM, Santoro E. Subtotal gastrectomy for gastric cancer: long term outcomes of Billroth I reconstruction at a single European institute. *Hepatogastroeterology* (In press).

113 **Bae JM**, Kim S, Kim YW, Ryu KW, Lee JH, Noh JH, Sohn TS, Hong SK, Park SM, You CH, Kim JH, Lee MK, Yun YH. Health-related quality of life among disease-free stomach cancer survivors in Korea. *Qual Life Res* 2006; **15**: 1587-1596 [PMID: 17036253 DOI: 10.1007/s11136-006-9000-8]

114 **Onodera H**, Tokunaga A, Yoshiyuki T, Kiyama T, Kato S, Matsukura N, Masuda G, Tajiri T. Surgical outcome of 483 patients with early gastric cancer: prognosis, postoperative morbidity and mortality, and gastric remnant cancer. *Hepatogastroenterology* 2004; **51**: 82-85 [PMID: 15011835]

115 **Takeda J**, Hashimoto K, Koufuji K, Tanaka T, Kodama I, Kakegawa T. Remnant-stump gastric cancer following partial gastrectomy. *Hepatogastroenterology* 1992; **39**: 27-30 [PMID: 1568702]

116 **Schroeder TJ**, Helling T, McKenna RM, Rush D, Jeffrey JR, Brewer B, Martin LA, Traylor D, Fisher RA, First MR. A multicenter study to evaluate a novel assay for quantitation of soluble interleukin 2 receptor in renal transplant recipients. *Transplantation* 1992; **53**: 34-40 [PMID: 1733082 DOI: 10.1002/bjs.5600]

117 **Carboni F**, Lepiane P, Santoro R, Lorusso R, Mancini P, Carlini M, Santoro E. Treatment for isolated loco-regional recurrence of gastric adenocarcinoma: does surgery play a role? *World J Gastroenterol* 2005; **11**: 7014-7017 [PMID: 16437608 DOI: 1007-9327/11/7014.asp]

118 **VISICK AH**. A study of the failures after gastrectomy. *Ann R Coll Surg Engl* 1948; **3**: 266-284 [PMID: 18112082]

119 **Davies J**, Johnston D, Sue-Ling H, Young S, May J, Griffith J, Miller G, Martin I. Total or subtotal gastrectomy for gastric carcinoma? A study of quality of life. *World J Surg* 1998; **22**: 1048-1055 [PMID: 9747165 DOI: 10.1007/s002689900515]

120 **Takiguchi S**, Yamamoto K, Hirao M, Imamura H, Fujita J, Yano M, Kobayashi K, Kimura Y, Kurokawa Y, Mori M, Doki Y. A comparison of postoperative quality of life and dysfunction after Billroth I and Roux-en-Y reconstruction following distal gastrectomy for gastric cancer: results from a multi-institutional RCT. *Gastric Cancer* 2012; **15**: 198-205 [PMID: 21993852 DOI: 10.1007/s10120-011-0098-1]

121 **Wang D**, Kong Y, Zhong B, Zhou X, Zhou Y. Fast-track surgery improves postoperative recovery in patients with gastric cancer: a randomized comparison with conventional postoperative care. *J Gastrointest Surg* 2010; **14**: 620-627 [PMID: 20108171 DOI: 10.1007/s11605-009-1139-5]

122 **Feng F**, Ji G, Li JP, Li XH, Shi H, Zhao ZW, Wu GS, Liu XN, Zhao QC. Fast-track surgery could improve postoperative recovery in radical total gastrectomy patients. *World J Gastroenterol* 2013; **19**: 3642-3648 [PMID: 23801867 DOI: 10.3748/wjg.v19.i23.3642]

123 **Chen ZX**, Liu AH, Cen Y. Fast-track program vs traditional care in surgery for gastric cancer. *World J Gastroenterol* 2014; **20**: 578-583 [PMID: 24574728 DOI: 10.3748/wjg.v20.i2.578]

124 **Kim HH**, Han SU, Kim MC, Hyung WJ, Kim W, Lee HJ, Ryu SW, Cho GS, Kim CY, Yang HK, Park do J, Song KY, Lee SI, Ryu SY, Lee JH. Prospective randomized controlled trial (phase III) to comparing laparoscopic distal gastrectomy with open distal gastrectomy for gastric adenocarcinoma (KLASS 01). *J Korean Surg Soc* 2013; **84**: 123-130 [PMID: 23396494 DOI: 10.4174/jkss.2013.84.2.123].]

125 **Parsonnet J**, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. *Lancet* 1996; **348**: 150-154 [PMID: 8684154 DOI: 10.1016/S0140-6736(96)01501-2]

126 **Xie F**, Luo N, Lee HP. Cost effectiveness analysis of population-based serology screening and (13)C-Urea breath test for Helicobacter pylori to prevent gastric cancer: a markov model. *World J Gastroenterol* 2008; **14**: 3021-3027 [PMID: 18494053 DOI: 10.3748/wjg.14.3021]

127 **Lee YC**, Lin JT, Wu HM, Liu TY, Yen MF, Chiu HM, Wang HP, Wu MS, Hsiu-Hsi Chen T. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. *Cancer Epidemiol Biomarkers Prev* 2007; **16**: 875-885 [PMID: 17507609 DOI: 10.1158/1055-9965.EPI-06-0758]

128 **Dan YY**, So JB, Yeoh KG. Endoscopic screening for gastric cancer. *Clin Gastroenterol Hepatol* 2006; **4**: 709-716 [PMID: 16765306 DOI: 10.1016/j.cgh.2006.03.025]

**P-Reviewer:** Amornyotin S, Fang WL,Obama K **S-Editor:** Qi Y **L-Editor: E-Editor:**